Liana S. Rosenthal

Liana S. Rosenthal

Auto-generated profile, based on publicly available information

Liana S. Rosenthal

Department of Neurology Johns Hopkins University School of Medicine Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2018 in Science
Verified
Journal Article
Closed access
PDF file
TKTae-In Kam
Tae-In Kam
Xiaobo MaoXiaobo Mao
Xiaobo Mao
HPHyejin Park
Hyejin Park
SCShih-Ching Chou
Shih-Ching Chou
Senthilkumar S. KaruppagounderSenthilkumar S. Karuppagounder
Senthilkumar S. Karuppagounder
VDValina L. Dawson
Valina L. Dawson
PAR promotes α-synuclein toxicity: How pathologic α-synuclein (α-syn) leads to neurodegeneration in Parkinson's disease (PD) remains poorly understood. Kam et al. studied the α-syn preformed fibril (α-syn PFF) model of sporadic PD (see the Perspective by Brundin and Wyse). They found that pathologic α-syn–activated poly(adenosine 5′-diphosphate–ribose) (PAR) polymerase–1 (PARP-1) and inhibition of PARP or knockout of PARP-1 protected mice from pathology. The generation of PAR by α-syn PFF–induced PARP-1 activation converted α-syn PFF to a strain that was 25-fold more toxic, termed PAR–α-syn PFF. An increase of PAR in the cerebrospinal fluid and evidence of PARP activation in the substantia nigra of PD patients indicates that PARP activation contributes to the pathogenesis of PD through parthanatos and conversion of α-syn to a more toxic strain. Science , this issue p. eaat8407 ; see also p. 521

15 August 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ACAlice S. Chen-Plotkin
Alice S. Chen-Plotkin
RARoger Albin
Roger Albin
RARoy Alcalay
Roy Alcalay
DBDebra Babcock
Debra Babcock
VBVikram Bajaj
Vikram Bajaj
JZJing Zhang
Jing Zhang
The recent advent of an “ecosystem” of shared biosample biorepositories and data sets will aid efforts to define biomarkers for Parkinson’s disease.

7 October 2015 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
LRLiana S. Rosenthal
Liana S. Rosenthal
DDDaniel Drake
Daniel Drake
RARoy N. Alcalay
Roy N. Alcalay
DBDebra Babcock
Debra Babcock
FBF. DuBois Bowman
F. DuBois Bowman
OCon behalf of the PDBP consortium
on behalf of the PDBP consortium

10 September 2024 in Neurology
Verified
Journal Article
Open access
JGJulia Gallagher
Julia Gallagher
CGCaroline Gochanour
Caroline Gochanour
CCChelsea Caspell-Garcia
Chelsea Caspell-Garcia
RDRoseanne D Dobkin
Roseanne D Dobkin
DADag Aarsland
Dag Aarsland
PIParkinson'S Progression Markers Initiative
Parkinson'S Progression Markers Initiative
It is widely cited that dementia occurs in up to 80% of patients with Parkinson disease (PD), but studies reporting such high rates were published over two decades ago, had relatively small samples, and had other limitations. We aimed to determine long-term dementia risk in PD using data from two large, ongoing, prospective, observational studies. Participants from the Parkinson's Progression Markers Initiative (PPMI), a multisite international study, and a long-standing PD research cohort at the University of Pennsylvania (Penn), a single site study at a tertiary movement disorders center, were recruited. PPMI enrolled de novo, untreated PD participants and Penn a convenience cohort from a large clinical center. For PPMI, a cognitive battery is administered annually, and a site investigator makes a cognitive diagnosis. At Penn, a comprehensive cognitive battery is administered either annually or biennially, and a cognitive diagnosis is made by expert consensus. Interval-censored survival curves were fit for time from PD diagnosis to stable dementia diagnosis for each cohort, using cognitive diagnosis of dementia as the primary end point and Montreal Cognitive Assessment (MoCA) score <21 and Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I cognition score ≥3 as secondary end points for PPMI. In addition, estimated dementia probability by PD disease duration was tabulated for each study and end point. For the PPMI cohort, 417 participants with PD (mean age 61.6 years, 65% male) were followed, with an estimated probability of dementia at year 10 disease duration of 9% (site investigator diagnosis), 15% (MoCA), or 12% (MDS-UPDRS Part I cognition). For the Penn cohort, 389 participants with PD (mean age 69.3 years, 67% male) were followed, with 184 participants (47% of cohort) eventually diagnosed with dementia. The interval-censored curve for the Penn cohort had a median time to dementia of 15 years (95% CI 13-15); the estimated probability of dementia was 27% at 10 years of disease duration, 50% at 15 years, and 74% at 20 years. Results from two large, prospective studies suggest that dementia in PD occurs less frequently, or later in the disease course, than previous research studies have reported.

18 January 2021 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
AHAnouk van der Heide
Anouk van der Heide
ASAnne E. M. Speckens
Anne E. M. Speckens
MMMarjan J. Meinders
Marjan J. Meinders
LRLiana S. Rosenthal
Liana S. Rosenthal
BBBastiaan R. Bloem
Bastiaan R. Bloem
RHRick C. Helmich
Rick C. Helmich
Many Parkinson’s disease (PD) patients notice that motor symptoms worsen during stress, and experience stress-related neuropsychiatric symptoms such as anxiety and depression. Here we investigated which personal and disease characteristics are associated with perceived stress in PD, which PD symptoms are sensitive to stress, and we assessed self-reported benefits of stress-reducing strategies such as mindfulness. We sent an online survey to the Fox Insight cohort (n = 28,385 PD patients, n = 11,413 healthy controls). The survey included specific questions about the influence of stress on PD symptoms, use of stress-reducing strategies, and several validated scales measuring perceived stress, anxiety, dispositional mindfulness, rumination, and self-compassion. We received completed surveys from 5000 PD patients and 1292 controls. Patients perceived more stress than controls. Among patients, stress was correlated with increased rumination (R = 0.65), lower quality of life (R = −0.56), lower self-compassion (R = −0.65), and lower dispositional mindfulness (R = −0.48). Furthermore, patients indicated that stress significantly worsened both motor symptoms – especially tremor – and non-motor symptoms. Physical exercise was most frequently used to reduce stress (83.1%). Mindfulness was practiced by 38.7% of PD respondents, who noticed improvement in both motor and non-motor symptoms. Among non-users, 43.4% were interested in gaining mindfulness skills. We conclude that PD patients experience greater levels of stress than controls, and that stress worsens both motor and non-motor symptoms. Mindfulness may improve PD symptom severity, with the strongest effects on anxiety and depressed mood. These findings justify further controlled studies to establish the merits of mindfulness and other stress-alleviating interventions.

1 May 2017 in Biomarkers in Medicine
Verified
Journal Article
Closed access
KGKatrina Gwinn
Katrina Gwinn
KDKaren K David
Karen K David
CSChristine Swanson-Fischer
Christine Swanson-Fischer
RARoger Albin
Roger Albin
CHCoryse St Hillaire-Clarke
Coryse St Hillaire-Clarke
LRLiana S Rosenthal
Liana S Rosenthal
Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's Disease Biomarker Program (PDBP) and other mechanisms, no single PD marker or set of markers are ready for clinical use. Here we discuss the current state of biomarker discovery for platforms relevant to PDBP. We discuss the role of the PDBP in PD biomarker identification and present guidelines to facilitate their development. These guidelines include: harmonizing procedures for biofluid acquisition and clinical assessments, replication of the most promising biomarkers, support and encouragement of publications that report negative findings, longitudinal follow-up of current cohorts including the PDBP, testing of wearable technologies to capture readouts between study visits and development of recently diagnosed (de novo) cohorts to foster identification of...